Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
45 Results for "
MBL
" in MedChemExpress (MCE) Product Catalog:
Products (45)
45 Results for "MBL" in MCE Product Catalog:
Cat. No.: HY-113590
CAS No.: 1019207-72-7
FR295389 is a dihydroimidazopyrazolium cephalosporin with antibacterial activity. FR295389 shows activity against IMP-type metallo-β-lactamases (MBL)-producing Klebsiella pneumoniae, Acinetobacter baumanii and Pseudomonas putida with MIC values ranging from 4 to 32 mg/mL .
Cat. No.: HY-175489
CAS No.: 1770826-25-9
Target:
Research Areas:
D-CS319 is a potent inhibitor of metallo-𝛽-lactamases (MBLs) with IC50 values of 2.0 and 3.0 μM for IMP-1 and IMP-78, respectively. D-CS319 has antibacterial activity .
Cat. No.: HY-161310
CAS No.: 1804934-57-3
Target:
Research Areas:
Metallo-β-lactamase-IN-15 (Compound ±13) is a potent MBL inhibitor, the IC50 values for NDM-1、IMP-1 and VIM-2 were 0.29 μM, 0.088 μM and 0.063 μM, respectively .
Cat. No.: HY-144259
CAS No.: 1501705-61-8
Target:
Research Areas:
Metallo-β-lactamase-IN-4 (compound 40) is a potent metallo-β-lactamases (MBL) inhibitor, with IC50 values of 0.1 μM (VIM-1), 1.3 μM (NDM-1), and 5.0 μM (IMP-7), respectively .
Cat. No.: HY-144262
CAS No.: 2711044-25-4
Target:
Research Areas:
Metallo-β-lactamase-IN-4 (compound 40) is a potent metallo-β-lactamases (MBL) inhibitor, with IC50 values of 0.5 μM (VIM-1), 2.1 μM (NDM-1), and 3.3 μM (IMP-7), respectively .
Cat. No.: HY-N6189
CAS No.: 1815632-13-3
Target:
Endogenous Metabolite COX p38 MAPK NF-κB NOD-like Receptor (NLR) NO Synthase Reactive Oxygen Species (ROS) Interleukin Related
Research Areas:
MBL-1 is an orally active anti-inflammatory agent. MBL-1 can be isolated from the fermentation broth of Aspergillus sp. derived from gorgonians. MBL-1 inhibits the activity of the hCOX-2 protein with an IC50 of 5.77 μM. MBL-1 reduces the production of key pro-inflammatory mediators such as NO, ROS, IL-1β and IL-18 by inhibiting the MAPK/NF-κB and NLRP3 signaling pathways. MBL-1 exerts a protective effect against DSS-induced colitis. MBL-1 can be used for the research of ulcerative colitis .
Cat. No.: HY-144261
CAS No.: 128294-71-3
Target:
Research Areas:
Metallo-β-lactamase-IN-3 (compound 35) is a potent metallo-β-lactamases (MBL) inhibitor. Metallo-β-lactamase-IN-3 shows high activity against VIM-1 and NDM-1, with IC50 of 0.6 and 1.0 μM, respectively. Metallo-β-lactamase-IN-3 does not show inhibition of IMP-7 .
Cat. No.: HY-155504
CAS No.: 3038740-18-7
Target:
Research Areas:
Metallo-β-lactamase-IN-11 (compound 5f) is a Metallo-β-lactamases (MBLs) inhibitor, potent against bacterial metallophyllactamase CphA (IC50=45 µM). Metallo-β-lactamase-IN-11 (10 µM) inhibits NDM-1 by 49% and AIM-1 by 61%. Metallo-β-lactamase-IN-11 can be used in the research of inhibiting antibiotic resistance .
Cat. No.: HY-143414
CAS No.: 1439899-44-1
Target:
Research Areas:
Metallo-β-lactamase-IN-6 is a potent VIM-Type metallo-β-lactamase inhibitor with IC50s of 0.56 μM, 29.50 μM and 5.78 μM for VIM-2, VIM-1 and VIM-5. Metallo-β-lactamase-IN-6 displays potent synergistic antibacterial activity with Meropenem against engineered Escherichia coli strains and intractable clinically isolated Pseudomonas aeruginosa producing VIM-2 MBL .
Cat. No.: HY-189006
CAS No.: 3066273-36-4
Target:
Research Areas:
MBL-IN-7 is a potent metallo-β-lactamase (MBLs) inhibitor. The IC50 values of MBL-IN-7 against NDM-1, IMP-1, VIM-1, VIM-2, and L1 are 11 nM, 69 nM, 29 nM, 12 nM, and 85 μM, respectively. MBL-IN-7 is an antibiotic adjuvant. MBL-IN-7 competitively inhibits enzyme activity primarily by coordinating with zinc ions in the active site of MBLs and forming hydrogen bonds and π interactions, thereby protecting carbapenem antibiotics from hydrolysis. MBL-IN-7 is applicable to research related to carbapenem-resistant Gram-negative bacterial infections .
Cat. No.: HY-P70281
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: MBL2; Mannose-Binding Lectin (Protein C) 2, Soluble; Prev. MBL; Mannose-Binding Lectin; COLEC1; Mannan-Binding Protein; MBP-C; Mannose Binding Lectin; MBP1; Mannan-Binding Lectin; MBP; Collectin 1; Mannose-Binding Lectin (Protein C) 2, Soluble (Opsonic De
Species:
Human
Source:
HEK293
Cat. No.: HY-P70674
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: MBL2; Mannose-Binding Lectin (Protein C) 2, Soluble; Prev. MBL; Mannose-Binding Lectin; COLEC1; Mannan-Binding Protein; MBP-C; Mannose Binding Lectin; MBP1; Mannan-Binding Lectin; MBP; Collectin 1; Mannose-Binding Lectin (Protein C) 2, Soluble (Opsonic De
Species:
Mouse
Source:
HEK293
Cat. No.: HY-189634
Target:
Research Areas:
Fmoc-FFC is a competitive MBL (NDM-1, VIM-2, and IMP-1) inhibitor with Ki values of 2.3, 6.0, and 7.1 μM, respectively. Fmoc-FFC alone has no antibacterial activity, but acts synergistically with Meropenem (HY-13678) to restore antibacterial activity against MBL/NDM-1-producing E. coli. Fmoc-FFC supports cell-cell adhesion and can serve as a scaffold for cell culture growth. Fmoc-FFC can be used in research on systemic infections caused by NDM-1-producing E. coli .
Cat. No.: HY-184667
CAS No.: 3115648-56-8
Research Areas:
β-Lactamase/Ferroptosis-IN-1 is a dual inhibitor of β-Lactamase and ferroptosis, β-Lactamase/Ferroptosis-IN-1 inhibits NDM-1 (metallo-β-lactamase, MBLs, IC50 = 1.8 μM) and KPC-2 (serine-β-lactamase, SBLs, IC50 = 2.6 μM). β-Lactamase/Ferroptosis-IN-1 exerts synergistic antibacterial effects with antibiotics against multidrug-resistant Gram-negative bacteria (MDR-GNB), and alleviates LPS (HY-D1056)-induced acute lung injury by inhibiting ferroptosis via upregulating FTH1 and GPX4 expression and reducing MDA levels. β-Lactamase/Ferroptosis-IN-1 can be used for the study of MDR-GNB infections and acute lung injury .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
